Mirabella Financial Services LLP Abb Vie Inc. Transaction History

Mirabella Financial Services LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $300,931 - $338,919	2,187 New	2,187 $338,000
Q2 2023 Aug 07, 2023	BUY	$132.51 - $164.9 $2.56 Million - $3.18 Million	19,309 New	19,309 $2.6 Million
Q3 2022 Oct 26, 2022	BUY	$134.21 - $153.93 $345,188 - $395,907	2,572 New	2,572 $367,000
Q2 2022 Aug 12, 2022	SELL	$137.62 - $174.96 $1.72 Million - $2.19 Million	-12,497 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$131.98 - $163.75 $1.65 Million - $2.05 Million	12,497 New	12,497 $2.03 Million
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $459,860 - $522,011	-4,322 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$105.21 - $117.21 $454,717 - $506,581	4,322 New	4,322 $487,000
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $2.01 Million - $2.71 Million	-24,913 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$85.91 - $100.83 $1.89 Million - $2.22 Million	21,988 Added 751.73%	24,913 $2.18 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $214,607 - $287,176	2,925 New	2,925 $287,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Mirabella Financial Services LLP, based on Form 13F filings with the SEC.

Stay updated on Mirabella Financial Services LLP with notifications on news.